Merck KGaA (MKGAF) - OTCPK - Current
  • Thu, May 19, 2:07 AM
    | Thu, May 19, 2:07 AM
  • Mar. 6, 2014, 8:26 AM
    • Merck's (MKGAF) Q4 EBITDA of $1.1B meets consensus estimate. Annual profit will be $4.45B slightly under the consensus target of $4.53B.
    • Q4 revenue fell 3.3% to $3.75B matching views.
    • The company is evaluating potential acquisitions as part of its plan to expand its footprint in the US, Japan and China.
    | Mar. 6, 2014, 8:26 AM
  • Nov. 14, 2013, 6:39 AM
    • Merck KGaA (MKGAF) Q3 EBITDA: €831M (+10% Y/Y), beats by €24M.
    • Revenue of €2.75B, misses by €20M.
    • Full year outlook: EBITDA of €3.2-3.25B versus previous guidance of €3.1-3.2B. (PR)
    | Nov. 14, 2013, 6:39 AM
  • Jul. 27, 2011, 3:09 AM

    Merck KGaA (MKGAF.PK) reports a Q2 net EPS loss of €0.40 ($0.58), vs. profit of €0.84 a year earlier. Revenue +16% to €2.56B. For 2011, Merck expects operating profit of about €1B, below guidance given in April, due to one-time adjustments.

    | Jul. 27, 2011, 3:09 AM | 2 Comments
Company Description
Merck KGaA is a global pharmaceutical, chemical and life science company with a history that began in 1668 and a future shaped by approximately 40,000 employees in 67 countries. Merck KGaA's subsidiaries in North America operate using the umbrella brand "EMD".
Sector: Healthcare
Industry: Drug Related Products
Country: Germany